



DURECT to Present at the BMO Capital Markets Focus on Healthcare Conference

CUPERTINO, Calif., July 28, 2010 /PRNewswire via COMTEX/ —

DURECT Corporation (Nasdaq: DRRX) announced today that Matthew J. Hogan, Chief Financial Officer, will be presenting at the BMO Capital Markets 10th Annual Focus on Healthcare Conference on Thursday, August 5 at 1:45 p.m. Eastern Time. The conference is being held at the Sheraton New York Hotel.

(Logo: <http://photos.prnewswire.com/prnh/20020717/DRRXLOGO>)

(Logo: <http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO>)

A live audio webcast of the presentation will be available by accessing:

<http://www.bmocm.com/conferences/2010healthcare/webcast>

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.

NOTE: POSIDUR(TM), SABER(TM), ORADUR(R), TRANSDUR(TM), and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

SOURCE DURECT Corporation